Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.81 |
| ▸ | CDK2 | P24941 | 20/20 | 0.81 |
| ▸ | CCND1 | P24385 | 17/20 | 0.81 |
| ▸ | CDK6 | Q00534 | 17/20 | 0.81 |
| ▸ | CDK4 | P11802 | 4/20 | 0.74 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.74 |
| ▸ | CDK9 | P50750 | 3/20 | 0.74 |
| ▸ | CCND3 | P30281 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19863598 | 0.89 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL24132136 | 0.88 | CCNE1 (0.79) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL24132123 | 0.88 | CCNE1 (0.79) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL29640992 | 0.87 | CCNE1 (0.84) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19863597 | 0.87 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL24132126 | 0.87 | CCNE1 (0.81) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL24132124 | 0.87 | CCNE1 (0.84) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857324 | 0.87 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL19857311 | 0.85 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL31153371 | 0.85 | CCNE1 (1.00) | CCNE1CDK2CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250018049-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| EP-4267575-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018049-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | CDK2, SKP2, CDK5 | CCNE1 36/4885CDK2 1/4885CCND1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.